Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal delivery system for the nebulization of
the lipid complex amphotericin B (Abelcet ®) in lung transplant recipients who are positive
for invasive aspergillosis (IA) in their lungs. Additionally, the investigators hope to
determine the concentrations of amphotericin B achieved in the epithelial lining fluid, and
serum with the administration of four days of lipid complex of amphotericin B (Abelcet ®)
(QD) via aerosolized nebulization